Overview

Beta-Blocker Evaluation in Survival Trial (BEST)

Status:
Completed
Trial end date:
1999-09-01
Target enrollment:
Participant gender:
Summary
To determine if addition of a beta-blocker to standard therapy in Class III and Class IV heart failure patients reduced total mortality.
Phase:
Phase 3
Details
Lead Sponsor:
National Heart, Lung, and Blood Institute (NHLBI)
Treatments:
Adrenergic Agents
Adrenergic beta-Antagonists